Author

Raja Atreya

GUSELKUMAB, AN IL-23P19 SUBUNIT–SPECIFIC MONOCLONAL ANTIBODY, BINDS CD64 ON THE SURFACE OF IL-23-SECRETING MYELOID CELLS, CAPTURES LOCALLY PRODUCED IL-23, AND DELIVERS IL-23 TO INTRACELLULAR COMPARTMENTS
GUSELKUMAB, AN IL-23P19 SUBUNIT–SPECIFIC MONOCLONAL ANTIBODY, BINDS CD64 ON THE SURFACE OF IL-23-SECRETING MYELOID CELLS, CAPTURES LOCALLY PRODUCED IL-23, AND DELIVERS IL-23 TO INTRACELLULAR COMPARTMENTS

Raja Atreya  et al.

BURDEN OF BOWEL URGENCY ACROSS SPECIFIC TREATMENT GROUPS AMONG CROHN’S DISEASE PATIENTS – REAL WORLD GLOBAL STUDY ANALYSES
BURDEN OF BOWEL URGENCY ACROSS SPECIFIC TREATMENT GROUPS AMONG CROHN’S DISEASE PATIENTS – REAL WORLD GLOBAL STUDY ANALYSES

Raja Atreya  et al.

BURDEN OF BOWEL URGENCY ACROSS SPECIFIC TREATMENT GROUPS AMONG CROHN’S DISEASE PATIENTS – REAL WORLD GLOBAL STUDY ANALYSES
BURDEN OF BOWEL URGENCY ACROSS SPECIFIC TREATMENT GROUPS AMONG CROHN’S DISEASE PATIENTS – REAL WORLD GLOBAL STUDY ANALYSES

Connecting the dots: Integrating mechanism of action into advanced treatment decisions in UC (Arena Pharmaceuticals)
Connecting the dots: Integrating mechanism of action into advanced treatment decisions in UC (Arena Pharmaceuticals)

Raja Atreya  et al.

Anti-IL23 and more
Anti-IL23 and more

Raja Atreya

Assessing ulcerative colitis: Is there something your patient isn’t telling you? (Eli Lilly and Company)
Assessing ulcerative colitis: Is there something your patient isn’t telling you? (Eli Lilly and Company)

Raja Atreya  et al.

JAK to the future: a patient-centric choice in UC (Galapagos)
JAK to the future: a patient-centric choice in UC (Galapagos)

Raja Atreya  et al.

EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES
EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES

Raja Atreya  et al.

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Raja Atreya  et al.

RAPID CLINICAL RESPONSE TO UPADACITINIB THERAPY IS ASSOCIATED WITH IMPROVED CLINICAL AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
RAPID CLINICAL RESPONSE TO UPADACITINIB THERAPY IS ASSOCIATED WITH IMPROVED CLINICAL AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Raja Atreya  et al.

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)
Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

Raja Atreya  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: FINAL RESULTS FROM THE PHASE 3 U-ENDURE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: FINAL RESULTS FROM THE PHASE 3 U-ENDURE STUDY

Raja Atreya  et al.

MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY
MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY

Raja Atreya  et al.

EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY
EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY

Raja Atreya  et al.

ADD-ON MULTIPLE SUBMUCOSAL INJECTIONS OF RNA OLIGONUCLEOTIDE GUT-1 TO TUMOR NECROSIS FACTOR-ANTAGONIST TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INVESTIGATOR-INITIATED TRIAL
ADD-ON MULTIPLE SUBMUCOSAL INJECTIONS OF RNA OLIGONUCLEOTIDE GUT-1 TO TUMOR NECROSIS FACTOR-ANTAGONIST TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INVESTIGATOR-INITIATED TRIAL

Raja Atreya  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Raja Atreya  et al.

PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE CROHN´S DISEASE PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY
PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE CROHN´S DISEASE PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY

Raja Atreya  et al.

ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY
ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY

Raja Atreya  et al.

TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Raja Atreya  et al.

EXPERT CONSENSUS TO STANDARDISE TRANSCRIPTOME ANALYSIS IN INFLAMMATORY BOWEL DISEASE CLINICAL TRIALS
EXPERT CONSENSUS TO STANDARDISE TRANSCRIPTOME ANALYSIS IN INFLAMMATORY BOWEL DISEASE CLINICAL TRIALS

Raja Atreya  et al.

Item 1 - 20 / 20
1